-+ 0.00%
-+ 0.00%
-+ 0.00%

Stifel Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $508

Benzinga·12/11/2025 13:16:23
Listen to the news
Stifel analyst Paul Matteis maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and raises the price target from $495 to $508.